Arphra
live
S&P 5007,511.35-0.57%
NASDAQ29,968.13-1.89%
DOW51,999.67+0.64%
VIX16.35-0.37%
US10Y4.43-0.94%
EUR/USD1.1506-0.93%
GOLD4,300.5-1.26%
WTI75.22-0.90%
BTC64,442.01-1.87%
S&P 5007,511.35-0.57%
NASDAQ29,968.13-1.89%
DOW51,999.67+0.64%
VIX16.35-0.37%
US10Y4.43-0.94%
EUR/USD1.1506-0.93%
GOLD4,300.5-1.26%
WTI75.22-0.90%
BTC64,442.01-1.87%

DXCM

DexCom, Inc.
HealthcareMedical - DevicesUSUSDPeers →
$72.47
LiveJun 18, 2026
AI Brief
Market cap
$27.96B
52w range
54.11 – 89.98
P / E
EPS · FY 2025
$2.09
Volume
7.63M
Revenue · FY 2025
$4.66B
+15.60% YoY

Explain this page

Arphra AI
Business description
· company · SEC profile

DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Founded
IPO
Apr 14, 2005
Employees
10,200
HQ
San Diego, CA
CEO
Jacob Steven Leach
CFO
Jereme Sylvain
Exchange
NASDAQ
Fiscal year